This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Sierra Leone

2. **Grant number:** 1821-SLE-12d-X/09-SLE-8b-Y/18-SLE-25a-Y

3. **Date of Decision Letter:** 5 March 2019

4. **Date of the Partnership Framework Agreement:** 31 October 2013

5. **Programme title:** New Vaccine Support (NVS), Pneumococcal Routine

6. **Vaccine type:** Pneumococcal

7. **Requested product presentation and formulation of vaccine:** Pneumococcal (PCV13), 4 doses per vial, LIQUID

8. **Programme duration:** 2010-2021

9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th></th>
<th>2010-2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>26,859,476³</td>
<td>1,594,000</td>
<td>2,593,000</td>
<td>2,689,000</td>
<td>33,735,476</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant (in US$):** A VIG of US$ 100,00 was disbursed to Sierra Leone on 28 May 2010

11. **Product switch grant:** Sierra Leone is eligible for a Product Switch Grant of US$ 75,533 to support the PCV switch

12. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2010-2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Pneumococcal vaccines doses</td>
<td></td>
<td>474,000</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>26,859,476³</td>
<td>1,594,000</td>
</tr>
</tbody>
</table>

13. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. **Self-procurement:** N/A

---

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2019 include the costs of injection safety devices. Annual amounts for 2019 onwards include only vaccine costs and freight.
15. **Co-financing obligations:** Reference code: 1821-SLE-12d-X-C

   According to the co-financing policy, the Country falls within the group Initial self-financing.

   The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>34,200</td>
<td>62,400</td>
<td>64,800</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>100,409</td>
<td>183,865</td>
<td>190,661</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>102,000</td>
<td>186,500</td>
<td>193,000</td>
</tr>
</tbody>
</table>

16. **Operational support for campaigns:** Not applicable

17. **Additional reporting requirements:**

<table>
<thead>
<tr>
<th>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>• vaccine stock levels including buffer stock, by end of March;</td>
<td>31 March 2019</td>
</tr>
<tr>
<td>• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</td>
<td>15 May 2019</td>
</tr>
</tbody>
</table>

   In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. To be agreed with Secretariat

18. **Financial clarifications:** Not applicable

19. **Other conditions:** Not applicable

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
5 March 2019
SIERRA LEONE
Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Sierra Leone
2. **Grant number:** 1821-SLE-04c-X
3. **Date of Decision Letter:** 5 March 2019
4. **Date of the Partnership Framework Agreement:** 31 October 2013
5. **Programme title:** New Vaccine Support (NVS), Pentavalent Routine
6. **Vaccine type:** Pentavalent
7. **Requested product presentation and formulation of vaccine:** DTP-HepB-Hib, 10 doses per vial, LIQUID
8. **Programme duration:** 2007 - 2021
9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Year</th>
<th>2007-2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>17,536,797&lt;sup&gt;3&lt;/sup&gt;</td>
<td>387,500</td>
<td>498,000</td>
<td>516,000</td>
<td>18,938,297</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant (in US$):** Not applicable
11. **Product switch grant:** Not applicable
12. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)<sup>4</sup>

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2007-2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Pentavalent vaccines doses</td>
<td></td>
<td>544,000</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>17,536,797&lt;sup&gt;5&lt;/sup&gt;</td>
<td>387,500</td>
</tr>
</tbody>
</table>

13. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
14. **Self-procurement:** Not applicable

<sup>1</sup> This is the entire duration of the Programme.
<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.
<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
<sup>4</sup> This is the amount that Gavi has approved.
<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2019 include the costs of injection safety devices. Annual amounts for 2019 onwards include only vaccine costs and freight.
15. Co-financing obligations: Reference code: 1821-SLE-04c-X-C

According to the co-financing policy, the Country falls within the Initial self-financing group. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>213,000</td>
<td>274,000</td>
<td>284,000</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>146,858</td>
<td>188,762</td>
<td>195,746</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>151,500</td>
<td>195,000</td>
<td>202,000</td>
</tr>
</tbody>
</table>

16. Operational support for campaigns: Not applicable

17. Additional reporting requirements:

<table>
<thead>
<tr>
<th>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>• vaccine stock levels including buffer stock, by end of March;</td>
<td>31 March 2019</td>
</tr>
<tr>
<td>• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</td>
<td>15 May 2019</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

18. Financial clarifications: Not applicable

19. Other conditions: Not applicable

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
5 March 2019
SIERRA LEONE
Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Sierra Leone
2. **Grant number:** 1821-SLE-13b-X / 12-SLE-08a-Y
3. **Date of Decision Letter:** 5 March 2019
4. **Date of the Partnership Framework Agreement:** 31 October 2013
5. **Programme title:** New Vaccine Support (NVS), Rotavirus Routine
6. **Vaccine type:** Rotavirus
7. **Requested product presentation and formulation of vaccine:** Rotavirus, 2 doses schedule
8. **Programme duration**: 2012 -2021
9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement, if applicable)
   
<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2012-2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4,986,661³</td>
<td>902,500</td>
<td>1,299,500</td>
<td>1,347,500</td>
<td>8,536,161</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant (in US$):** US$ 193,500 disbursed on 6 May 2014
11. **Product switch grant:** Not applicable
12. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2012-2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Rotavirus vaccines doses</td>
<td></td>
<td>388,500</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>4,986,661⁵</td>
<td>902,500</td>
</tr>
</tbody>
</table>

13. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
14. **Self-procurement:** N/A

---

¹ This is the entire duration of the Programme.
² This is the total amount endorsed by Gavi for the entire duration of the Programme.
³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
⁴ This is the amount that Gavi has approved.
⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2019 include the costs of injection safety devices. Annual amounts for 2019 onwards include only vaccine costs and freight.
15. **Co-financing obligations**: Reference code: 1821-SLE-13b-X-C  
According to the co-financing policy, the Country falls within the group Initial self-financing.  
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>37,500</td>
<td>54,000</td>
<td>55,500</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>82,789</td>
<td>119,227</td>
<td>123,600</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>85,500</td>
<td>123,000</td>
<td>127,500</td>
</tr>
</tbody>
</table>

16. **Operational support for campaigns**: N/A

17. **Additional reporting requirements**:

| To prepare for the annual procurement of vaccines, Country shall submit the following information each year:  
• vaccine stock levels including buffer stock, by end of March;  
• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.  
Countries shall report the actual switch date in the first renewal request following the actual implementation. | Due dates |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>31 March 2019</td>
</tr>
<tr>
<td></td>
<td>15 May 2019</td>
</tr>
</tbody>
</table>

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.  
To be agreed with Secretariat

18. **Financial clarifications**: N/A

19. **Other conditions**: N/A

On behalf of Gavi

Hind Khatib-Othman  
Managing Director, Country Programmes  
5 March 2019
SIERRA LEONE
Support for Yellow Fever Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Sierra Leone

2. **Grant number:** 1821-SLE-06b-X

3. **Date of Decision Letter:** 5 March 2019

4. **Date of the Partnership Framework Agreement:** 31 October 2013

5. **Programme title:** NVS, Yellow Fever Routine

6. **Vaccine type:** Yellow Fever

7. **Requested product presentation and formulation of vaccine:** Yellow Fever, 10 doses per vial, LYOPHILISED

8. **Programme duration**: 2003 -2021

9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2003-2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>3,087,452³</td>
<td>381,500</td>
<td>392,000</td>
<td>412,500</td>
<td>4,273,452</td>
<td></td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant (in US$):** Not applicable

11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2003-2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Yellow Fever vaccines doses</td>
<td>3,087,452⁵</td>
<td>312,200</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>381,500</td>
<td></td>
</tr>
</tbody>
</table>

---

¹ This is the entire duration of the Programme.
² This is the total amount endorsed by Gavi for the entire duration of the Programme.
³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
⁴ This is the amount that Gavi has approved.
⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2019 include the costs of injection safety devices. Annual amounts for 2019 onwards include only vaccine costs and freight.
12. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. **Self-procurement:** N/A

14. **Co-financing obligations:** **Reference code:** 1821-SLE-06b-X-C

   According to the co-financing policy, the Country falls within the group Initial self-financing.

   The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>61,200</td>
<td>61,800</td>
<td>65,000</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>71,543</td>
<td>72,814</td>
<td>76,629</td>
</tr>
<tr>
<td>Total co-financing payments (US$ (including freight))</td>
<td>75,000</td>
<td>76,000</td>
<td>80,000</td>
</tr>
</tbody>
</table>

15. **Operational support for campaigns:** Not applicable

16. **Additional reporting requirements:**

<table>
<thead>
<tr>
<th>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>• vaccine stock levels including buffer stock, by end of March;</td>
<td>31 March 2019</td>
</tr>
<tr>
<td>• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</td>
<td>15 May 2019</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>
17. Financial clarifications: N/A

18. Other conditions: There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
5 March 2019
SIERRA LEONE
Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone

2. Grant number(s): 19-SLE-25c-X / 15-SLE-08h-Y

3. Date of Decision Letter: 5 March 2019

4. Date of the Partnership Framework Agreement: 31 October 2013

5. Programme title: NVS, IPV routine

6. Vaccine type: Inactivated Polio Vaccine (IPV)

7. Requested product presentation and formulation of vaccine: Inactivated Polio Vaccine, 10 doses per vial, LIQUID

8. Programme duration: 2015 - 2019

9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement, if applicable)

   - Routine Programme (US$) 2015-2018: 224,061
   - Total Budget (US$) 2015-2018: 224,061
   - 2019: 931,500
   - Total: 1,155,561

   Total 2015-2018 to 2019: 1,155,561

10. Vaccine introduction grant: US$ 180,000 disbursed on 8 May 2015

11. Product switch grant: Not applicable

12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Number of vaccines to be purchased with Gavi funds</th>
<th>2015-2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV Routine Programme (doses)</td>
<td>406,300</td>
<td></td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>224,061</td>
<td>931,500</td>
</tr>
</tbody>
</table>

13. Procurement agency: UNICEF

---

1 Please refer to section 18 for additional information on IPV presentation.
2 This is the entire duration of the Programme.
3 This is the total amount endorsed by Gavi for 2015 to 2019.
4 This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
5 This is the amount that Gavi has approved.
14. **Self-procurement:** Not applicable

15. **Co-financing obligations:** Not applicable
   
   Gavi’s usual co-financing requirements do not apply to IPV. However, Sierra Leone is encouraged to contribute to vaccine and/or supply costs for IPV.

16. **Operational support for catch-up campaigns:** Not applicable

17. **Additional reporting requirements:**

<table>
<thead>
<tr>
<th>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</th>
<th>Due dates</th>
</tr>
</thead>
</table>
   | • vaccine stock levels including buffer stock, by end of March;  
   | • number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.  
   | Countries shall report the actual switch date in the first renewal request following the actual implementation. | 31 March 2019  
   | | 15 May 2019 |

   In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.  
   | To be agreed with Secretariat |

18. **Financial clarifications:** Not applicable

19. **Other conditions:**

   Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

   If Sierra Leone envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Sierra Leone.

On behalf of Gavi

Hind Khatib-Othman  
Managing Director, Country Programmes  
5 March 2019